drugset / Trial / NCT00089869

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

NCT00089869

Phase 1/2 Completed Eli Lilly and Company
Treatment

Summary

Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified
Subject Olanzapine Small molecule

Indications